Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Erdosteine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Erdosteine | DRUG | - |
Inclusion Criteria: * Adult patients with a clinical diagnosis of stable CB associated with COPD will be entered into this study. CB is diagnosed clinically in patients who have a documented smoking history and who have a daily productive cough for at least 3 months per year over at least 2 consecu...
Erdosteine is an investigational small molecule being developed for chronic bronchitis. It is also being studied in patients with chronic obstructive pulmonary disease (COPD). The drug is currently in Phase 2 clinical development and has not been approved by the FDA.
Erdosteine is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research on this small molecule for respiratory conditions.
Erdosteine is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind study with 400 participants. The drug remains investigational and has not received FDA approval.
Erdosteine has one completed clinical trial, registered as NCT00338507. This Phase 2 study enrolled 400 patients with chronic bronchitis and COPD in the United States. The trial was randomized and double-blind, with a minimum participant age of 40 years.
Erdosteine is a distinct small molecule developed by cbdMD, Inc. No alternative names have been reported for this drug. It is being studied specifically for chronic bronchitis and COPD, and is not known to be identical to any other marketed medication.